Vosevi (sofosbuvir;velpatasvir;voxilaprevi)
- Region
- 🇪🇺 EU
- Active substance
- sofosbuvir;velpatasvir;voxilaprevi
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- Hepatitis C, Chronic
- CHMP opinion
- Thu 22 Jun 2017
- EU approval
- Wed 26 Jul 2017
- Application
- EMEA/H/C/004350
- ATC
- J05A
- Official record
- www.ema.europa.eu
Indication
Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Vosevi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.